Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH

27-09-2017 | Image

Figure 1

The loss or the inhibition of either of the protein products of gene A or B alone or the overexpression of gene A is viable (part a). Mutation (part b) or pharmacological inhibition (part c) of the protein product of gene B in cells with a mutation (parts b,c) or overexpression (part d) of gene A results in synthetic lethality. The thicker arrow denotes increased expression. The star shape denotes a mutation. The red crosses denote pharmacological inhibition. Viable cells are depicted as ovals, and inviable cells are depicted as random shapes.

print
PRINT
Image Credits